Product Images Gemcitabine

The text provides information about progression-free probability in a medical study comparing the drugs Gemcitabine and Carboplatin. The study involved 178 patients and shows that the median progression-free survival for Gemcitabine/Carboplatin was 8.6 months compared to 5.8 months for Carboplatin alone. The study found a p-value of 0.0038, suggesting the difference in survival rates between the two drugs is statistically significant. Additionally, the provided graph shows the progression-free survival over a period of 24 months.*

This is a comparison of the progression-free probability of two treatments for documented disease progression. The first is a combination of Gemcitabine and Pacitaxel, and the second is only Paciitaxel. The median time for the combination treatment is 5.2 months, while for Pacitaxel only, it is 2.9 months. The significance level of this result is p <0.0001, indicating a statistically significant difference between the treatments. The graph shows time to documented disease progression in months for each treatment.*

The given text represents a chart that has two cancer treatment options, 5-FU and Gemcitabine, on the x-axis and fraction surviving percentages on the y-axis. The chart is also depicting the survival time in months (8, 12, and 16) at which the treatment is given to the patients.*

Gemcitabine Injection is a cytotoxic injection used for intravenous use. The injection is stored in 263mL single-dose vials which must be diluted before use. Each vial contains 1g of gemcitabine with water for injection. The pH level is adjusted using hydrochloric acid and/or sodium hydrovide. The drug is distributed by Hospira Inc, Lake Forest, IL. It is essential to exercise great caution while using the drug to prevent inhaling particles and exposing the skin to it. No other information is readable from the given text.*

Gemcitabine is a potentially cytotoxic agent used for injection. Each vial contains 200mg gemcitabine and water for injection. Hydrochloric acid and/or sodium hydroxide may be added for pH adjustment. Gemcitabine is highly toxic and care should be taken to prevent inhaling particles and exposing the skin to it. The drug must be diluted prior to intravenous use, and unused portion should be discarded. The drug is distributed by Hospira, Inc.*

This is a description of a medication called Gemcitabine Injection, which comes in a 2g vial of gemcitabine and Water for Injection, USP. It is a cytotoxic agent that must be diluted before intravenous use, and should be stored between 2 and 8°C. The pH may be adjusted using hydrochloric acid, NF and/or sodium hydroxide, NF. Caution should be taken not to inhale particles or expose skin to the drug. The medication is distributed by Hospira, Inc. in Lake Forest, IL, USA.*